EYEGATE PHARMACEUTICALS INC EYEG Balance Sheet

Eyegate pharmaceuticals inc (EYEG)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14
ASSETS
Current Assets:
Cash and Cash Equivalents
5,877	3,776	2,454	4,465	5,855	8,004	9,900	12,604	3,648	7,806	9,244	11,763	5,437	3,635	5,682	8,026	7,214	8,394	9,919	1,273	2,285	167
Unbilled Revenue
-	-	-	-	-	-	-	-	922	-	-	-	-	-	-	-	-	-	-	-	-	-
License and Grant Fees Receivable
-	-	-	-	-	-	-	-	-	-	602	146	109	37	37	45	337	907	-	-	-	0
Prepaid Expenses and Other Current Assets
366	458	528	551	698	455	663	614	731	629	360	519	863	464	527	676	748	122	83	133	180	26
Right-of-Use Assets
145	83	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-Use Assets
-	-	-	109	97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Portion of Refundable Tax Credit Receivable
5	4	4	1	6	18	17	14	25	23	21	17	18	16	16	27	26	25	25	22	23	25
Total Current Assets
6,394	4,324	3,112	5,127	6,658	8,478	10,581	13,234	5,328	8,459	10,228	12,446	6,429	4,154	6,262	8,776	8,327	9,449	10,028	1,430	2,489	218
Property and Equipment, Net
16	16	23	30	36	43	50	39	47	55	24	28	33	38	42	0	0	0	0	0	0	1
Restricted Cash
45	45	45	45	45	45	45	45	45	45	45	45	45	45	45	45	30	20	20	20	20	0
Goodwill
1,525	1,525	1,525	1,525	1,525	1,525	1,525	-	-	1,525	-	-	-	-	-	-	-	-	-	-	-	-
Intangible Assets and In-Process R&D, Net
4,124	4,131	4,137	4,143	4,149	4,156	4,162	-	-	3,912	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill and In-Process R&D
-	-	-	-	-	-	-	5,438	5,438	-	5,438	5,438	5,438	5,438	-	-	-	0	-	-	-	-
In-Process Research and Development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,212	3,912	3,912	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	68	0	-
Other Assets
81	69	23	23	23	31	287	307	307	307	323	354	55	55	53	49	46	38	37	37	36	-
Total Non-Current Assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,353	4,006	-	-	-	-	-	-
Other assets, including deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,186
Total Assets
12,187	10,112	8,867	10,895	12,439	14,280	16,652	19,064	11,166	14,305	16,059	18,313	12,001	9,730	10,616	12,783	12,316	9,507	10,086	1,556	2,547	1,406
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Grants payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	36
Accounts Payable
158	210	1,067	96	244	63	324	356	221	706	658	970	1,310	1,412	1,403	1,229	869	417	158	337	286	565
Accrued Expenses
491	1,120	982	737	578	1,114	1,147	1,041	1,409	1,813	1,724	1,166	862	1,670	1,339	1,311	910	1,095	250	304	126	913
Lease Liabilities
145	83	125	109	97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue
-	-	0	-	-	2,686	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue
-	-	-	-	0	-	2,686	2,723	2,860	12,313	10,254	8,861	8,225	4,225	3,418	2,563	2,659	1,907	1,000	-	-	0
Contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,210	-	-	-	-	-
Convertible notes due to stockholders, net (aggregate principal outstanding of $0 and $3,376,573, at December 31, 2015 and 2014, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,205
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	303
Total Current Liabilities
794	1,414	2,175	943	919	3,864	4,157	4,120	4,491	14,833	12,637	10,998	10,398	7,308	6,161	5,104	5,649	3,420	1,408	642	412	5,024
Non-Current Liabilities:
Contingent Consideration
1,710	1,710	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	1,210	-	0	-	-	-	-
Deferred Tax Liability
365	365	269	-	-	269	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liability
-	-	-	-	-	-	-	-	-	-	-	-	-	1,525	-	-	-	-	-	-	-	-
Deferred Tax Liability
-	-	-	269	269	-	183	183	183	183	1,525	1,525	1,525	-	-	-	-	0	-	-	-	-
Long-Term Portion of Capital Financing Obligation
-	-	-	-	-	-	0	1	3	4	6	9	12	16	-	-	-	0	-	-	-	-
Total Non-Current Liabilities
2,075	2,075	1,479	1,479	1,479	1,479	1,394	1,395	1,397	1,398	2,742	2,745	2,748	2,751	-	-	-	0	-	-	-	-
Total Liabilities
2,869	3,490	3,655	2,423	2,399	5,344	5,551	5,516	5,888	16,232	15,379	13,744	13,147	10,060	7,371	6,314	-	3,420	-	-	-	-
Commitments and Contingencies (Note 10)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	-	-	-	0	0	0	0	0
Non-controlling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	6,780
Total convertible preferred stock and non-controlling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	43,189
Stockholders' Equity:
Preferred Stock, $0.01 Par Value: 9,994,184 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding at March 31, 2020 and December 31, 2019; 10,000 designated Series B, 0 shares issued and outstanding at March 31, 2020 and December 31, 2019; 10,000 shares designated Series C, 4,092 shares issued and outstanding at March 31, 2020 and December 31, 2019
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	0	0	0	0
Common Stock, $0.01 Par Value: 120,000,000 shares authorized; 4,626,755 and 4,077,755 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
46	40	30	456	455	30	434	423	172	172	172	172	108	101	95	89	83	76	76	64	63	2
Common Stock Issuable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	205	291	-	-	-	-	-
Additional Paid-In Capital
111,330	106,689	102,588	101,996	101,729	101,921	101,150	100,492	89,694	89,589	89,366	89,177	80,201	78,106	77,991	77,639	73,934	71,209	71,121	62,012	61,723	10,055
Accumulated Deficit
-102,199	-100,246	-97,545	-94,116	-92,279	-93,150	-90,622	-87,498	-84,718	-91,816	-88,985	-84,845	-81,518	-78,598	-74,897	-71,521	-67,697	-65,255	-62,565	-61,209	-59,668	-56,862
Stockholders Notes Receivable
-	-	-	-	-	-	-	-	-	-	0	58	58	58	58	58	58	58	58	58	58	58
Accumulated Other Comprehensive Income
139	139	137	135	133	134	137	130	128	127	126	123	120	120	114	113	114	114	103	104	74	56
Total Stockholders' Equity
9,317	6,622	5,211	8,471	10,039	8,936	11,100	13,548	5,278	-1,926	679	4,569	-1,146	-329	3,245	6,468	6,666	6,086	8,677	913	2,134	-46,806
Total Liabilities and Stockholders' Equity
12,187	10,112	8,867	10,895	12,439	14,280	16,652	19,064	11,166	14,305	16,059	18,313	12,001	9,730	10,616	12,783	12,316	9,507	10,086	1,556	2,547	1,406